A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer

Xin Zhou; Zebo Huang; Lei Xu; Mingxia Zhu; Lan Zhang; Huo Zhang; Xiaping Wang; Hai Li; Wei Zhu; Yongqian Shu; Ping Liu

doi:10.18632/oncotarget.11903

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer

Xin Zhou, Zebo Huang, Lei Xu, Mingxia Zhu, Lan Zhang, Huo Zhang, Xiaping Wang, Hai Li, Wei Zhu, Yongqian Shu and Ping Liu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:69616-69624. https://doi.org/10.18632/oncotarget.11903

Metrics: PDF 2006 views | HTML 3545 views | ?

Abstract

Xin Zhou1,*, Zebo Huang1,*, Lei Xu2,*, Mingxia Zhu1, Lan Zhang1, Huo Zhang1, Xiaping Wang3, Hai Li4, Wei Zhu1, Yongqian Shu1,5, Ping Liu1,5

1Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

2Department of Thoracic Surgery, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210029, China

3Department of Pathology, Sir Run Run Hospital Affiliated With Nanjing Medical University, Nanjing 211166, China

4Department of Pathology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, PR China

5Cancer Center of Nanjing Medical University, Nanjing 210029, China

*These authors contributed equally to this work

Correspondence to:

Ping Liu, email: [email protected]

Wei Zhu, email: [email protected]

Keywords: pancreatic cancer, miRNA, signature, biomarker, prognosis

Received: August 09, 2015 Accepted: September 02, 2016 Published: September 08, 2016

ABSTRACT

Some reports have evaluated the prognostic relevance of microRNAs (miRNAs) in patients with pancreatic cancer (PC). However, most studies focused on limited miRNAs with small number of patients. The aim of the study is to identify a panel of miRNA signature that could predict prognosis in PC with the data from The Cancer Genome Atlas (TCGA). A total of 167 PC patients with the corresponding clinical data were enrolled in our study. The miRNAs significantly associated with overall survival (OS) in PC patients were identified with Cox proportional regression model. A risk score formula was developed to evaluate the prognostic value of the miRNA signature in PC. Thirteen miRNAs were identified to be significantly related with OS in PC patients. Patients with high risk score suffered poor overall survival compared with patients who had low risk score. The multivariate Cox regression analyses showed that the miRNA signature could act as an independent prognostic indicator. In addition, the signature might serve as a predicator for treatment outcome. Our study identified a miRNA signature including 13 miRNAs which could serve as an independent marker in prognosis of PC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11903

Publication Alerts

Research Papers:

A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer

Abstract